DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...

With this in mind perhaps, Dexcom has launched its Stelo device ... for its products having mass-market appeal, in order to keep the share price buoyant. I have fallen into this trap myself ...

Q4 2024 Management View Kevin Sayer, CEO, highlighted that Q4 2024 organic revenue growth was 8%, contributing to a full-year organic growth of 12%, aligned with guidance. The company ended 2024 with ...

Here’s what investors should know. DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, driving momentum and market ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

In March 2024, the Food and Drug Administration cleared Dexcom’s Stelo as the first over-the ... Additionally, eating foods in a specific order—like eating the lettuce and tomato first ...

Dexcom leveraged Google Cloud’s cutting-edge Vertex AI platform and Gemini models as the foundation to build its proprietary GenAI platform. Stelo, the first over-the-counter glucose biosensor ...

Dexcom’s focus on expanding continuous glucose monitoring access, rolling out new products like the Stelo, and its plans ... on the stock with a $100.00 price target. TipRanks tracks over ...

The flagship G7 and DexCom ONE+ platforms continued to drive adoption internationally, with launches in key regions such as France, Australia and Japan bolstering growth. Early success with the newly ...